This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n11http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064173%3A_____%2F10%3A00002653%21RIV13-MZ0-00064173/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064173%3A_____%2F10%3A00002653%21RIV13-MZ0-00064173
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated the long-term outcomes of these transplants and aimed to identify potential prognostic factors. Methods: In this observational study we analyzed all first autologous hematopoietic stem cell trans plants for autoimmune diseases reported to the European Group for Blood and Marrow Transplantation (EBMT) registry between 1996-2007. The primary end-points for analysis were overall survival, progression-free survival and trans plant-related mortality at 100 days. Results improved with time and were associated with the transplant centers' experience. These data support ongoing and planned phase III trials to evaluate the place of autologous hematopoietic stem cell transplantation in the treatment strategy for severe autoimmune diseases. Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated the long-term outcomes of these transplants and aimed to identify potential prognostic factors. Methods: In this observational study we analyzed all first autologous hematopoietic stem cell trans plants for autoimmune diseases reported to the European Group for Blood and Marrow Transplantation (EBMT) registry between 1996-2007. The primary end-points for analysis were overall survival, progression-free survival and trans plant-related mortality at 100 days. Results improved with time and were associated with the transplant centers' experience. These data support ongoing and planned phase III trials to evaluate the place of autologous hematopoietic stem cell transplantation in the treatment strategy for severe autoimmune diseases.
dcterms:title
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases
skos:prefLabel
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases
skos:notation
RIV/00064173:_____/10:00002653!RIV13-MZ0-00064173
n4:aktivita
n14:N
n4:aktivity
N
n4:cisloPeriodika
2
n4:dodaniDat
n15:2013
n4:domaciTvurceVysledku
n12:1463268
n4:druhVysledku
n13:J
n4:duvernostUdaju
n10:S
n4:entitaPredkladatele
n7:predkladatel
n4:idSjednocenehoVysledku
248154
n4:idVysledku
RIV/00064173:_____/10:00002653
n4:jazykVysledku
n16:eng
n4:klicovaSlova
hematologic immune cytopenia; juvenile idiopathic arthritis; rheumatoid arthritis; systemic lupus erythematosus; systemic sclerosis; multiple sclerosis; autoimmune diseases; autologous hematopoietic stem cell transplantation
n4:klicoveSlovo
n6:hematologic%20immune%20cytopenia n6:rheumatoid%20arthritis n6:systemic%20lupus%20erythematosus n6:juvenile%20idiopathic%20arthritis n6:multiple%20sclerosis n6:autoimmune%20diseases n6:systemic%20sclerosis n6:autologous%20hematopoietic%20stem%20cell%20transplantation
n4:kodStatuVydavatele
IT - Italská republika
n4:kontrolniKodProRIV
[5FEE14C95A3C]
n4:nazevZdroje
Haematologica - The Hematology Journal
n4:obor
n9:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
14
n4:rokUplatneniVysledku
n15:2010
n4:svazekPeriodika
95
n4:tvurceVysledku
Kozák, Tomáš
n4:wos
000274803700017
s:issn
0390-6078
s:numberOfPages
9
n11:doi
10.3324/haematol.2009.013458